News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK)'s Ebola Vaccine To Be Tested For Safety In Humans As Early As Next Week



8/27/2014 5:31:55 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

U.S. scientists will begin enrolling patients as soon as next week in clinical safety trials of GlaxoSmithKline Plc (GSK)’s experimental Ebola vaccine as the death toll from the disease rises in West Africa.

The National Institutes of Health’s Vaccine Research Center received approval from the Food and Drug Administration to start the Phase 1 trial, Michael Kurilla, director of the Office of Biodefense, Research Resources and Translational Research, said today in a telephone interview. A Phase 1 trial is the first test of a drug or vaccine in humans to assess safety and whether it works similarly to how it does in animals.

Help employers find you! Check out all the jobs and post your resume.

Read at BusinessWeek
Read at Reuters
Read at NBC
Read at BBC News
Read at Guardian


comments powered by Disqus
BusinessWeek
Reuters
NBC
BBC News
Guardian
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES